Dr. Reddy's Laboratories Ltd.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. carries a market capitalization of 1.13T, placing it among publicly traded companies globally. Its enterprise value stands at 1.12T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dr. Reddy's Laboratories Ltd.'s next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. has 832.98M shares outstanding.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. trades at a trailing price-to-earnings ratio of 34.16. The price-to-sales ratio is 3.42, and the price-to-book ratio stands at 2.95.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. trades at an EV/EBITDA multiple of 20.59 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.67 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Dr. Reddy's Laboratories Ltd. trades at an EV/FCF ratio of 89.82, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.12T versus a market cap of 1.13T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.60, indicating elevated leverage, while an interest coverage ratio of 13.12 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. posted a return on equity (ROE) of 9.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.06 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.05, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.55, useful for judging operating efficiency across full business cycles. The company generates approximately 11.97M in revenue per employee across its workforce of 27,669.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.99 indicates how many times Dr. Reddy's Laboratories Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. recorded 8.58B in income tax expense. That works out to an effective tax rate of 20.77, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 41.30B, leaving 33.11B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Dr. Reddy's Laboratories Ltd.'s stock has declined approximately 3.86% over the past 52 weeks. The 50-day moving average sits at 1,191.95, while the 200-day moving average is 1,243.52.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. generated 331.19B in revenue and converted that into 33.11B in net income, yielding earnings per share of 39.25. EBITDA reached 54.60B, while operating income came in at 36.06B.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. holds 81.43B in cash and equivalents against 71.95B in total debt, resulting in a net debt position of 46.48B. Total book value stands at 383.43B, with working capital of 141.99B providing operational flexibility.

Dr. Reddy's Laboratories Ltd. produced 41.20B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.98B in capital expenditures, free cash flow totaled 9.22B - equivalent to 11.06 per share.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. posted a gross margin of 53.00, reflecting its pricing power and cost economics. The operating margin of 10.89 and net profit margin of 10.00 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. paid dividends of 7.99 per share. The dividend payout ratio of 20.59 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.81, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.21, meaning Dr. Reddy's Laboratories Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dr. Reddy's Laboratories Ltd.'s most recent stock split took place on October 28, 2024 with a 1:5 split ratio.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. has an Altman Z-Score of 6.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.